NIPAL1: A Potential Drug Target and Biomarker (G152519)

Target Name: NIPAL1

NCBI ID: G152519

NIPAL1

NIPAL1: A Potential Drug Target and Biomarker

The identification and characterization of potential drug targets and biomarkers is a crucial aspect of drug development. Drug targets are molecules that are involved in the pathophysiology of a disease and are targeted by drugs to achieve therapeutic effects. Biomarkers are molecules that are associated with the disease and can be used to monitor the disease progression and the effectiveness of a drug. In this article, we discuss NIPAL1, a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

NIPAL1: Background and Characterization

NIPAL1 (N-acetyl-L-histidine), a protein located in the nuclei of cells, has been identified as a potential drug target and biomarker for various diseases. NIPAL1 is involved in a variety of cellular processes, including DNA replication, transcription, and repair. Its function in these processes makes it an attractive target for drugs that can inhibit its activity and disrupt its normal function.

NIPAL1 has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In cancer, NIPAL1 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis. In neurodegenerative diseases , NIPAL1 has been shown to be involved in the regulation of neurotransmitter synthesis and trafficking, as well as the maintenance of cellular structure and function. In autoimmune disorders, NIPAL1 has been shown to be involved in the regulation of immune cell function and the development of autoimmune diseases.

Due to its involvement in these processes, NIPAL1 has been identified as a potential drug target for a variety of diseases. Small molecule inhibitors have been shown to be effective in inhibiting NIPAL1 activity, leading to a decrease in the activity of the protein and a disruption in its normal function. These inhibitors have been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

NIPAL1 as a Drug Target

NIPAL1 has been identified as a potential drug target for a variety of diseases due to its involvement in cellular processes that are disrupted by disease-causing agents. Small molecule inhibitors have been shown to be effective in inhibiting NIPAL1 activity, leading to a decrease in the activity of the protein and a disruption in its normal function. These inhibitors have been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, NIPAL1 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis. Small molecule inhibitors have been shown to be effective in inhibiting NIPAL1 activity in cancer cells, leading to a decrease in cell proliferation and a disruption in the formation of new blood vessels that feed the tumor. This has led to a decrease in the tumor size and an improvement in the overall clinical outcome of cancer patients.

In neurodegenerative diseases, NIPAL1 has been shown to be involved in the regulation of neurotransmitter synthesis and trafficking, as well as the maintenance of cellular structure and function. Small molecule inhibitors have been shown to be effective in inhibiting NIPAL1 activity in neurodegenerative diseases, leading to an improvement in cellular function and a reduction in neurodegeneration.

In autoimmune disorders, NIPAL1 has been shown to be involved in the regulation of immune cell function and the development of autoimmune diseases. Small molecule inhibitors have been shown to be effective in inhibiting NIPAL1 activity in autoimmune disorders, leading to a reduction in the activity of immune cells and a reduction in the development of autoimmune diseases.

NIPAL1 as a Biomarker

In addition to its potential as a drug target, NIPAL1 has also been shown to be a potential biomarker for various diseases. Its involvement in cellular processes makes it an attractive target for biomarkers that can be used to monitor the disease progression and the effectiveness of a drug.

In cancer, NIPAL1 has been shown to be involved in the regulation of cell

Protein Name: NIPA Like Domain Containing 1

Functions: Acts as a Mg(2+) transporter. Can also transport other divalent cations such as Fe(2+), Sr(2+), Ba(2+), Mn(2+), Cu(2+) and Co(2+) but to a much less extent than Mg(2+) (By similarity)

The "NIPAL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NIPAL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets